ITGAM and neoplasm: Analysis of tumor immune profiles with flow cytometry showed that treatment with MRTX1133 decreased tumor infiltration of bone-marrow–derived monocytes (CD11b+Ly6ChiLy6G–) and, particularly macrophages (CD11b+F4/80+IA/IE+) and protumoral macrophages (ARG1+ macrophages) (Figure 2J).